Caring for HIV-infected patients in the ICU in the highly active antiretroviral therapy era

Current HIV Research

Volumn 7, Issue 6, 2009, Pages 569-579

  Corona, Alberto ^a   Raimondi, Ferdinando ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Critically ill patients; Epidemiology; Highly active antiretroviral therapy; HIV infection; Hospitalization; ICU

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CARNITINE; CORTICOSTEROID; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THIAMINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACUTE KIDNEY TUBULE NECROSIS; ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BACTEREMIA; BONE MARROW SUPPRESSION; CASE MANAGEMENT; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CRITICAL ILLNESS; CRYPTOCOCCOSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY LIVER; FEVER; GLUCOSE INTOLERANCE; HEART DISEASE; HEPATITIS; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INSULIN RESISTANCE; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; KAPOSI SARCOMA; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; MONOTHERAPY; MORTALITY; MYALGIA; MYCOBACTERIOSIS; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PROGNOSIS; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CRITICAL ILLNESS; HIV; HIV INFECTIONS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; TIME FACTORS;

EID: 73949106510     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209789973592     Document Type: Review

References (70)

1. Schein RM, Fischl MA, Pitchenik AE, Sprung CL. ICU survival of patients with the acquired immunodeficiency syndrome. Crit Care Med 1986; 14(12): 1026-7.
2. Layon AJ, D'Amico R. Intensive care for patients with acquired immunodeficiency syndrome - medicine versus ideology. Crit Care Med 1990; 18(11): 1297-9.
3. Friedman Y, Franklin C. Admission of AIDS patients to a medical intensive care unit: causes and outcomes. Crit Care Med 1990; 18(3): 346-7.
4. Smith RL, Levine SM, Lewis ML. Prognosis of patients with AIDS requiring intensive care. Chest 1989; 96(4): 857-61.
5. Wachter RM, Luce JM, Lo B, Raffin TA. Life-sustaining treatment for patients with AIDS. Chest 1989; 95(3): 647-52.
6. Rogers PL, Lane HC, Henderson DK, Parrillo J, Masur H. Admission of AIDS patients to a medical intensive care unit: causes and outcome. Crit Care Med 1989; 17(2): 113-7.
7. Luce JM, Wachter RM. Intensive care for patients with the acquired immunodeficiency syndrome. Intensive Care Med 1989; 15(8): 481-2.
8. Luce JM, Wachter RM, Hopewell PC. Intensive care of patients with the acquired immunodeficiency syndrome: time for a reassessment? Am Rev Respir Dis 1988; 137(6): 1261-3.
9. Deam R, Kimberley AP, Anderson M, Soni N. AIDS in ICUs: outcome. Anaesthesia 1988; 43(2): 150-1.
10. Huang L, Quartin A, Jones D, Havlir DV. Intensive Care of Patients with HIV Infection. N. Engl J Med 2006; 355: 173-81.
11. Morris A, Masur H, Huang L. Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med 2006; 34(1): 42-9.
12. Rosen MJ, Narasimhan M. Critical Care of Immunocompromised patients: Human immunodeficiency virus. Crit Care Med 2006; 34(Suppl 9): S245-50.
13. Corona A, Raimondi F. Critical care of HIV-infected patients in the highly active antiretroviral therapy era. Minerva Anestesiol 2007; 73(12): 635-45.
14. Lazard T, Retel O, Guidet B, Maury E, Valleron AJ, Offenstadt G. AIDS in a medical intensive care unit: immediate prognosis and long-term survival. JAMA 1996; 276(15): 1240-5.
15. De Palo VA, Millstein BH, Mayo PH, Salzman SH, Rosen MJ. Outcome of intensive care in patients with HIV infection. Chest 1995; 107(2): 506-10.
16. Franklin C, Friedman Y, Wong T, Hu TC. Improving long-term prognosis for survivors of mechanical ventilation in patients with AIDS with PCP and acute respiratory failure. Five-year follow-up of intensive care unit discharges. Arch Intern Med 1995; 155(1): 91-5.
17. Curtis JR, Greenberg DL, Hudson LD, Fisher LD, Krone MR, Collier AC. Changing use of intensive care for HIV-infected patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1994; 150(5 Pt 1): 1305-10.
18. Bennett RL, Gilman SC, George L, Guze PA, Bennett CL. Improved outcomes in intensive care units for AIDS-related Pneumocystis carinii pneumonia: 1987-1991. J Acquir Immune Defic Syndr 1993; 6(12): 1319-21.
19. Masur H. Caring for AIDS patients in the ICU: Expanding Horizons. Chest 2009; 135 (1): 1-2.
20. Brown J, Sprung CL. Ethical considerations in the treatment of AIDS patients in the intensive care unit. Crit Care Clin 1993; 9(1): 115-23. Review.
21. Rosen MJ, De Palo VA. Outcome of intensive care for patients with AIDS. Crit Care Clin 1993; 9(1): 107-14.
22. Davaro RE, Thirumalai A. Life-threatening complication of HIV-infection. J Intensive Care Med 2007; 22(2): 73-81.
23. Wachter RM, Luce JM, Turner J, Volberding P, Hopewell PC. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis 1986; 134(5): 891-6.
24. Banks RA, Lindley KJ, Pozniak AL. AIDS: a problem for intensive care. Intensive Care Med 1985; 11(4): 169-71.
25. Rosen MJ. Intensive care of patients with HIV infection. Semin Respir Infect 1999; 14(4): 366-71.
26. Gill JK, Greene L, Miller R. et al. ICU admission in patients infected with the human immunodeficiency virus - a multicentre survey. Anaesthesia 1999; 54(8): 727-32.
27. Leifeld L, Rockstroh J, Skaide S. et al. Indication, outcome and follow up of intensive care in patients with HIV-infection. Eur J Med Res 2000; 5(5): 199-202.
28. Bonarek M, Morlat P, Chene. et al. Prognostic score of short-term survival in HIV-infected patients admitted to medical intensive care units. Int J STD AIDS 2001; 12(4): 239-44.
29. Wachter RM, Luce JM, Hopewell PC. Critical care of patients with AIDS. JAMA 1992; 267(4): 541-7.
30. Morris A, Creasman J, Turner J, Luce JM, Wachter RM, Huang L. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166(3): 262-7.
31. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004; 18(10): 1429-33.
32. Afessa B, Green B. Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 2000; 118(1): 138-45.
33. Palacios R, Hidalgo A, Reina C, de la Torre M, Marquez M, Santos J. Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit. HIV Med 2006; 7(3): 193-6.
34. Nuesch R, Geigy N, Schaedler E, Battegay M. Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-Infected patients. Eur J Clin Microbiol Infect Dis 2002; 21(9): 684-68.
35. Vincent B, Timsit JF, Auburtin M, et al. Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 2004; 30(5): 859-66.
36. Khouli H, Afrasiabi A, Shibli M, Hajal R, Barrett CR, Homel P. Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J Intensive Care Med 2005; 20(6): 327-33.
37. Rees PH. HIV/AIDS: the first 25 years - a view from Nairobi. East Afr Med J 2008; 85(6): 292-300.
38. Zulu I, Schuman P, Musonda R, et al. Priorities for antiretroviral therapy research in sub-Saharan Africa: a 2002 consensus conference in Zambia. J Acquir Immune Defic Syndr 2004; 36(3): 831-4.
39. Jeena PM, McNally LM, Stobie M, et al. Challenges in the provision of ICU services to HIV-Infected children in resource poor settings: a South African case study. J Med Ethics 2005; 31(4): 226-30.
40. Sobhani R, Basavaraj A, Gupta A, et al. Mortality & clinical characteristics of hospitalized adult patients with HIV in Pune, India. Indian J Med Res 2007; 126(2): 116-21.
41. Croda J, Croda MG, Neves A, De Sousa dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med 2009; 37(5): 1605-11.
42. Powell K, Davis L, Morris AM, Chi A, Bensley MR, Huang L. Survival for patients with HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest 2009; 135(1): 11-17.
43. Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005; 128(2): 573-9.
44. Petrosillo N, Nicastri E, Viale P. Nosocomial pulmonary infections in HIV-positive patients. Curr Opin Pulm Med 2005; 11(3): 231-5.
45. Franzetti F, Grassini A, Piazza M, et al. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 2006; 34: 9-16.
46. Rosen MJ, Clayton K, Schneider RF, et al. Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155(1): 67-71.
47. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocistis pneumonia. Emerg Infect Dis 2004; 10: 1713-20.
48. Miller RF, Allen E, Copas A, Singer M, Edwards SG. Improved survival for HIV-infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2007; 62(11): 964-8.
49. Brenner M, Ognibene FP, Lack EE, et al. Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am Rev Respir Dis 1987; 136: 1199-206.
50. Kales CP, Murren JR, Torres RA, Crocco JA. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1987; 14: 1413-7.
51. Benfield TL, Helweg-Larsen J, Bang D, Junge J, Lundgren JD. Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Chest 2001; 119(3): 844-51.
52. Bédos JP, Dumoulin JK, Gachot B, et al. Pneumocystis carinii pneumonia requiring intensive care management: survival and prognostic study in 110 patients with human immunodeficiency virus. Crit Care Med 1999; 27(6): 1109-15.
53. Forrest DM, Zala C, Djurdjev O, et al. Determinants of short and long-term outcome in patients with respiratory failure caused by AIDS related Pneumocystis carinii pneumonia. Arch Intern Med 1999; 159 (7): 741-7.
54. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17(1): 73-80.
55. Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005; 5: 374-82.
56. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: results from the DAD study. AIDS 2003; 17(8): 1179-93.
57. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. (access date: July, 17th 2009).
58. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40 (11): 1559-85.
59. Chattha G, Arieff AI, Cummings C, Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118: 37-9.
60. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-Infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-73.
61. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIVinfected patients. Clin Infect Dis 2004; 38: 1159-66.
62. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81(3): 213-27.
63. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348 (8): 702-10.
64. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (http: //www.AIDSinfo.nih.gov.) (access date: July, 17th 2009).
65. Aberg JA, Gallant JE, Anderson J, et al. HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004; 39(5): 609-29.
66. Aceti A, Pasquazzi C, Zechini B, De Bac C; LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29: 41-8.
67. Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reversetranscriptase inhibitors: A case-control study. Clin Infect Dis 2003; 36: 1324-8.
68. Claessens YE, Cariou A, Monchi M, et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Crit Care Med 2003; 31(4) : 1042-7.
69. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352: 291-2.
70. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases. Ann Intern Med 2000; 133: 192-6.